Taiwan · Delayed Price · Currency is TWD MARX Biotech Statistics
Total Valuation
MARX Biotech has a market cap or net worth of TWD 2.93 billion. The enterprise value is 3.21 billion.
| Market Cap | 2.93B |
| Enterprise Value | 3.21B |
Important Dates
The last earnings date was Thursday, May 28, 2026.
| Earnings Date | May 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MARX Biotech has 521.98 million shares outstanding. The number of shares has increased by 4.77% in one year.
| Current Share Class | 521.98M |
| Shares Outstanding | 521.98M |
| Shares Change (YoY) | +4.77% |
| Shares Change (QoQ) | +6.43% |
| Owned by Insiders (%) | 22.57% |
| Owned by Institutions (%) | n/a |
| Float | 336.83M |
Valuation Ratios
The trailing PE ratio is 70.25.
| PE Ratio | 70.25 |
| Forward PE | n/a |
| PS Ratio | 4.61 |
| PB Ratio | 8.16 |
| P/TBV Ratio | 10.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 74.68 |
| EV / Sales | 5.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -20.28 |
Financial Position
The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.85.
| Current Ratio | 1.78 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.94 |
| Interest Coverage | -10.38 |
Financial Efficiency
Return on equity (ROE) is 13.82% and return on invested capital (ROIC) is -16.44%.
| Return on Equity (ROE) | 13.82% |
| Return on Assets (ROA) | -11.36% |
| Return on Invested Capital (ROIC) | -16.44% |
| Return on Capital Employed (ROCE) | -27.08% |
| Weighted Average Cost of Capital (WACC) | 7.86% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 80 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 1.69 |
Taxes
In the past 12 months, MARX Biotech has paid 15.60 million in taxes.
| Income Tax | 15.60M |
| Effective Tax Rate | 26.99% |
Stock Price Statistics
The stock price has decreased by -4.99% in the last 52 weeks. The beta is 0.74, so MARX Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | -4.99% |
| 50-Day Moving Average | 5.95 |
| 200-Day Moving Average | 5.11 |
| Relative Strength Index (RSI) | 42.67 |
| Average Volume (20 Days) | 2,401,712 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MARX Biotech had revenue of TWD 635.85 million and earned 42.92 million in profits. Earnings per share was 0.08.
| Revenue | 635.85M |
| Gross Profit | 394.59M |
| Operating Income | -142.15M |
| Pretax Income | 57.78M |
| Net Income | 42.92M |
| EBITDA | -128.15M |
| EBIT | -142.15M |
| Earnings Per Share (EPS) | 0.08 |
Balance Sheet
The company has 34.77 million in cash and 306.69 million in debt, with a net cash position of -271.92 million or -0.52 per share.
| Cash & Cash Equivalents | 34.77M |
| Total Debt | 306.69M |
| Net Cash | -271.92M |
| Net Cash Per Share | -0.52 |
| Equity (Book Value) | 359.38M |
| Book Value Per Share | 0.69 |
| Working Capital | 240.39M |
Cash Flow
In the last 12 months, operating cash flow was -148.73 million and capital expenditures -9.34 million, giving a free cash flow of -158.06 million.
| Operating Cash Flow | -148.73M |
| Capital Expenditures | -9.34M |
| Depreciation & Amortization | 14.00M |
| Net Borrowing | 33.70M |
| Free Cash Flow | -158.06M |
| FCF Per Share | -0.30 |
Margins
Gross margin is 62.06%, with operating and profit margins of -22.36% and 6.75%.
| Gross Margin | 62.06% |
| Operating Margin | -22.36% |
| Pretax Margin | 9.09% |
| Profit Margin | 6.75% |
| EBITDA Margin | -20.15% |
| EBIT Margin | -22.36% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 1.03%.
| Dividend Per Share | 0.06 |
| Dividend Yield | 1.03% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.77% |
| Shareholder Yield | -3.76% |
| Earnings Yield | 1.46% |
| FCF Yield | -5.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 11, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Jul 11, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
MARX Biotech has an Altman Z-Score of 4.19 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.19 |
| Piotroski F-Score | 3 |